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In multiple myeloma (MM), the strategy of com-bining therapeutic intensification with autologous stem cell transplantation (ASCT) may improve 
outcomes in terms of response rate and survival.1 
Currently, the majority of autologous transplants are 
performed using peripheral stem cells.2 After the collec-
tion of autologous stem cells the conventional practice is 
to freeze each collection product through cryopreserva-
tion. This procedure requires expensive equipment and 
trained personal. To avoid the high costs of establishing 
and maintaining a cryopreservation facility, efforts have 
been made to perform autografts without the use of 
cryopreservation devices.. Although non-cryopreserved 
storage of hematopoietic stem cells is not a standard 
practice, several reports have shown that autografts can 
be performed safely without cryopreservation devices, 
keeping the stem cells in a conventional blood bank re-
frigerator, at 4°C, for up to 4 days.3-10
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BACKGROUND AND OBJECTIVES: We evaluated the efficacy and safety of non-cryopreserved storage of 
autologous hematopoietic stem cells with no post-transplant granulocyte colony-stimulating factor (G-Csf) 
support in adult patients undergoing autologous stem cell transplantation (asCt) for multiple myeloma (mm).
DESIGN AND SETTING: retrospective review of patients undergoing asCt from may 2009 to July 2011.
PATIENTS AND METHODS: autologous stem cell were mobilized using G-Csf. Leukapheresis to harvest stem 
cells was performed on day -2 and -1. the grafts were kept in a conventional blood bank refrigerator at 4°C 
until reinfusion on day 0. the conditioning regimen consisted of melphalan 200 mg/m2 in all patients. the post-
chemotherapy myeloablative phase was managed without growth factors.
RESULTS: Between may 2009 to July 2011, 54 adults with mm were treated in our center in oran. the median 
age at asCt was 55 years (range, 35-65). there were 37 males and 17 females. the median harvested CD34+ 
cell count was 3.60×106/kg (range, 1.90 to 10.52). all patients had neutrophil engraftment on the median of day 
10 (range, 6-17) and platelet transfusion independence on the median of day 13 (range 9-24). in the 47 evalu-
able patients the median post-transplant overall survival had not been reached; the estimated overall survival 
at 30 months was 93.8% (0.05%) , and the estimated disease-free survival at 27 months was 93.6% (0.05%).
CONCLUSION: high-dose chemotherapy and asCt using non-cryopreserved stem cells and no G-Csf support 
is safe and feasible in the treatment of mm under our work conditions in developing countries.
In Europe and in the United States, the standard of 
care is administration of growth factors to accelerate 
neutrophil recovery after ASCT. The need for growth 
factors after transplant has been investigated recently.11 
Most of these studies are from the advanced countries, 
and data from developing countries such North Africa 
are scanty. We report our experience in patients with 
MM treated with a simplified autografting procedure 
in a single institution (Department of Hematology and 
cell therapy, Etablissement Hospitalier Universitaire 
[EHU], 1st November, Oran, Algeria) using non-cryo-
preserved stem cells.
PATIENTS AND METHODS
From May 2009 to July 2011, 78 ASCT were carried 
out in our center, of which 54 were for patients younger 
than the age 65 years, presenting with MM. Diagnosis 
of MM was based on the following findings:12-14 (a) 
original research report SiMPliFied STeM Cell TranSPlanTaTiOn
Hematol Oncol Stem Cell Ther 5(1)     First Quarter 2012 hemoncstem.edmgr.com50
increased numbers of abnormal, atypical or imma-
ture plasma cells in the bone marrow or histological 
proof of plasmacytoma; (b) presence of an M-protein 
in the serum or urine or (c) bone lesions consistent 
with those of MM. ASCT was indicated in all patients 
younger than the age of 65 years suffering from stage II 
or III symptomatic MM, with no major comorbidities. 
Normal renal and liver function tests were required 
for inclusion. Written informed consent was obtained 
before any procedure. All patients had been treated be-
fore the autograft as follows: 17 patients with vincris-
tine, doxorubicin and dexamethasone (VAD), 14 with 
bortezomib-dexamethasone (VD), 11 with VAD/
VD, and 12 with bortezomib, thalidomide, dexameth-
asone (VTD). Patients were admitted to a single room 
and reverse barrier nursing was practiced.
The source of stem cells in all patients consisted 
of mobilized autologous PBSCs. For mobilization of 
PBSCs, patients received granulocyte colony-stimu-
lating growth factor (G-CSF) at a dose of 15 mcg/kg 
subcutaneously once daily for 5 days. Leukapheresis 
was performed on days -2 and -1. A volume of 8-10 
L of blood was processed in each sitting, using the 
aphaeresis machine OPTIA (Cobe, Spectra). A me-
dian of one leukapheresis was performed (range, 1-2). 
Leukapheresis was done from the femoral vein in all 
patients using a dialysis catheter. A sample of the stem 
cell harvest was obtained and total cell counts were de-
termined using an automated cell counter; the differ-
ential cell count was done manually. For CD34 counts, 
cells were labeled with fluorescein-conjugated anti-
CD34 and analyzed using a FACS scan flowcytom-
eter to yield an absolute CD34+ count. The viability 
of cells was determined by a trypan blue dye exclusion 
test.
The products of the aphaeresis and 1-mL aliquots 
were kept in ACD-A (Baxter Healthcare, Deerfield, 
IL) and stored in a conventional blood bank refrig-
erator at 4°C, in 300-mL transfer packs (Baxter 
Healthcare) composed of gas impermeable, polyvinyl 
chloride plastic film. Stem cells were re-infused intra-
venously to the patient on day 0, 24 hours after mel-
phalan chemotherapy. To do this, stem cells were re-
moved from the conventional blood bank refrigerator 
and thawed at room temperature.
The myeloablative regimen consisted of melphalan 
200 mg/m2 (Glaxo-SmithKline, Uxbridge, Middlesex, 
UK) in a single intravenous dose, on day -1 in all pa-
tients, followed by ondansetron (8 mg intravenously 
every 12 h) and forced alkaline diuresis. Autologous 
PBSCs were re-infused on day 0 through a central ve-
nous catheter preceded by the administration of phe-
niramine maleate 50 mg intravenously. Post-transplant 
no patients received growth factor (G-CSF). All pa-
tients received prophylactic ciprofloxacin (250 mg 
twice daily), acyclovir (500 mg/day) and fluconazole 
(200 mg twice daily). Antibiotics were used until gran-
ulocytes were greater than 0.5×109/L. All patients had 
daily laboratory workup and clinical evaluation. Blood 
products transfused during the post-transplant period 
were irradiated with 25 Gy.
Cases of non-hematological dysfunction were con-
sidered regimen-related toxicities unless they could be 
clearly explained by another cause. A grading scale15 
was used for toxic complications of transplant: grade 
0 represented no toxicity; grade 1 toxicity was fully re-
versible without specific intervention; grade 2 toxicity 
was not life threatening, but required specific measures 
to be reversed; grade 3 was life threatening but revers-
ible; and grade 4 toxicity was fatal.
Engraftment was calculated from day 0 of the SCT. 
Neutrophil engraftment required a sustained absolute 
neutrophil count of 500/µL for 3 consecutive days. 
Engraftment of platelets required a platelet count of 
20,000/µL (un-transfused), with no platelet transfu-
sions within the preceding 48 hours. Evaluation of 
response to transplantation was assessed on day-100 
post-transplant. The criteria for response were the fol-
lowing: Complete response (CR) was defined as the 
absence of paraprotein on serum electrophoresis and 
5% or fewer plasma cells in the marrow. Very good 
partial response (VGPR) was defined as a decrease of 
90% in the serum paraprotein level, partial response 
(PR) as a decrease of 50% in the serum paraprotein 
level and minimal response as a decrease of 25% in the 
serum paraprotein level.16
Overall survival (OS) was defined as the time 
from date of transplant until death or date of censor. 
Disease-free survival (DFS) was evaluated in all pa-
tients who have achieved a complete response (CR) 
or VGPR after transplantation. It was calculated 
from the day of first documentation of CR or VGPR 
to the day of relapse or death. The analyses were per-
formed using SPSS software version 15.0 (IBM Corp, 
Armonk, NY USA). The Kaplan-Meier method was 
used to assess survival. The median follow-up was 10 
months (range, 3-30 months). The data were censored 
on 31 July 2011.
RESULTS
From May 2009 to July 2011, 78 ASCT were per-
formed in our center in Oran including 54 patients with 
MM, 37 men and 17 women, with a median age of 55 
years (range, 35-65). Table 1 shows some of the clinical 
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characteristics of these patients. The type of paraprotein 
was IgG in 29 cases, IgA in 16 cases and light chain dis-
ease in 9 cases. According to the International Staging 
System17 43 patients had stage III MM. The status of 
patients pre-transplant after induction treatment was 
as follows: 21 patients in CR (39%); 18 VGPR (33%) 
and 15 PR (28%). 
A median of one aphaeresis sessions was needed to 
collect a minimum of 1×106 CD34+ viable cells per kg 
of the recipient; the range was 1 to 2 sessions to obtain 
enough CD34+ cells. The median CD34+ cells har-
vested was 3.60×106/kg body weight; (range 1.90 to 
10.52×106/kg). As mentioned above, grafts were pre-
served in conventional blood bank refrigerator at +4°C 
for one day. In all cases, the viability of the CD34+ cells 
was above 85% before being re-infused to the patients. 
There were neither febrile episodes nor other side ef-
fects of the PBSC re-infusion in any case.
The median time to neutrophil engraftment) was 
10 days (range, 6-17 days) and median time for plate-
let transfusion independence was 13 days (range, 9-24 
days). After transplant, patients received a median of 2 
units of red blood cells (range, 0-9) and 1 unit of single 
donor platelet transfusion (range, 0-3) (Table 2). Post-
transplant no patients received growth factors (G-CSF).
Of the 54 autografted patients, 47 were assessable as 
being beyond the 100th post-transplant day. Of the lat-
ter, 42 achieved a CR (89%), 1 VGPR (2%) and 4 a PR 
(9%). The number of CR+ VGPR increased from 72% 
before to 91% after ASCT. The 100-day mortality was 
0%. In these 47 assessable patients, the median post-
transplant overall survival had not been reached; the 30 
month-overall survival was 93.8% ±0.05 (Figure 1) and 
the 27 months DFS was 93.6% ±0.05 (Figure 2).
Grade II mucositis (n=26), grade II-III nausea/
vomiting (n=54) and grade II alopecia (n=54) were the 
common non-hematologic toxicities. No patient had 
evidence of engraftment syndrome18 as evidenced by 
weight gain, fever, dyspnea, pleural effusion, skin rash 
and impaired liver and renal functions.
DISCUSSION
In Algeria, the prevalence of MM was 1.1/100 000 and 
the frequency of patients under the age of 40 years was 
25%,19 due to the youth of population.20 Among 13 he-
matology centers in Algeria, only two centers can offer 
ASCT to MM patients.21 The EHU 1st November 
from Oran is the second center. Our ASCT program 
started in May 2009 and has implemented the practice 
of keeping the stem cells in a conventional blood bank 
refrigerator.
Firstly, evaluation of our results obtained in terms 
Table 1. Patient characteristics.
Number Range
all patients 54 -
   Patient’s sex
    Male 37 -
    Female 17 -
age (years) 55 35-65
iSS myeloma stage
    ii 11 -
    iii 43 -
Monoclonal paraprotein type
igg 29
iga 16
light chain 9
Kappa/lambda 29/25
aphaeresis sessions 
performed 1 (median) 1-2
autologous Cd34+ve cells 
harvested (×106/kg) 3.65 (median) 1.9-10.52
Table 2. results.
Number Range
all patients 54 -
days of hospitalization after 
transplant 14 (median) 10-25
granulocyte recovery (days) 10 (median) 06-17
Platelet recovery (days) 13 (median) 09-24
red blood cells units 
transfused 2 (median) 00-9
number of single donor 
platelets transfused 1 (median) 00-3
Mucositis grade
   grade 0 7
   grade 1 22
   grade 2 19
   grade 3 6
Transplant related mortality 0*
*applicable to 47 accessible patients
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of engraftment (duration of hospitalization, neutrophil 
and platelets recovery), showed the feasibility and safety 
of ASCT without prior cryopreservation of hemato-
poietic stem cells (HSC), and thus validates this tech-
nique in our center. The advantages of this technique lie 
in the fact that it “avoids” the use of cryopreservation, 
an expensive process that requires special equipment as 
well as liquid nitrogen for freezing to –180°, the con-
sumables, albumin and dimethylsulfoxide (DMSO)
(fluid retention CSH) . Moreover, the simple preserva-
tion of HSC in a blood bank refrigerator at +4°C until 
re-infusion into the patient is devoid of any toxic side ef-
fects that are described with DMSO.22 This technique 
also has the advantage of reducing the time between the 
last induction chemotherapy and ASCT. The only con-
Figure 1. Overall survival.
Figure 1. disease free survival.
straint to this method is the need for a rigorous organi-
zation of scheduling patients on this protocol.
Secondly, the standard of care after myeloablative 
chemotherapy and reinfusion of autologous PBSCs is 
the initiation of growth factors (typically G-CSF) on 
day 5, continuing this agent daily until a neutrophil 
count of 500/µL has been achieved for three consecu-
tive days.23 However, growth factors may potentially 
increase the number and severity of some of the fluid-
related complications after transplant, such as acute re-
spiratory distress syndrome, allergic reactions, alveolar 
hemorrhage and, rarely, splenic rupture.24 Furthermore, 
growth factors come with substantial costs; as of 26 
January 2010 the retail price for a single dose of peg-
filgrastim was $3526.88 and that of 10 syringes of 480 
mcg filgrastim was $4621.83 (http://drugstore.com, 
accessed January 2010).
The need for growth factors after ASCT in MM 
has been investigated recently. Gertz et al showed that 
a neutrophil count of 500/µL was achieved in a median 
of 12.5 days in patients receiving growth factor, com-
pared with 13.5 days in those not receiving growth fac-
tor (P<.001). Platelet engraftment was identical (me-
dian, 14.5 days; P=.12) in both groups.11 Of note, the 
median hospital stay was 3.5 days shorter in the group 
not receiving growth factor in this study and the au-
thors concluded that it is feasible and reasonable to per-
form autologous SCT for multiple myeloma without 
administering growth factors. Our study show similar 
results of satisfactory engraftment with a median time 
to neutrophil recovery of 10 days (range 6-17) and me-
dian time to platelet transfusion independence of 13 
days (range, 9-24) without the use of growth factors.
 The results of our study in MM patients are ac-
ceptable and clearly superior to those obtained with 
conventional chemotherapy in the same institution.25,26 
We have been able to reproduce the results obtained by 
autografting MM patients in more advanced countries 
and, as a result, to offer this therapeutic option to pa-
tients living in Algeria who could not afford the cost of 
a conventional autografting procedure. 
Using this approach, the cost of ASCT in our coun-
try is expected to be substantially lower than that re-
ported in Europe.27,28 This cost saving procedure is 
critical in developing countries.29 These data are to be 
taken into account when considering treatment options 
in MM patients, mainly in developing countries.30,31 
This study demonstrates the feasibility of intensi-
fied therapy followed by autologous non-cryopreserved 
HSCs infusion in MM patients. Furthermore, it is fea-
sible not to administer growth factors post ASCT in 
this setting without adversely affecting outcome.
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SCT activities in other hematology centers in Algeria 
and in developing countries.
This method of ASCT in MM is cheaper, and may 
potentially enable the widespread use of autologous 
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